醋酸兰瑞肽(Lanreotide Acetate) - 药物靶点：SSTR_在研适应症：垂体肿瘤，巨人症，胃肠胰神经内分泌肿瘤_专利_临床

概要

基本信息

药物类型

合成多肽

别名

Angiopeptin、Dermopeptin、Ipstyl

+ [25]

靶点

SSTR

作用方式

拮抗剂

作用机制

SSTR拮抗剂(生长抑素受体拮抗剂)

治疗领域

肿瘤神经系统疾病消化系统疾病+ [3]

在研适应症

垂体肿瘤巨人症胃肠胰神经内分泌肿瘤+ [5]

非在研适应症

乳腺癌去势抵抗性前列腺癌脱水+ [17]

原研机构

Ipsen Pharma Biotech SAS

在研机构

Ipsen Pharma Biotech SASIpsen Pty Ltd.Ipsen Ltd.

+ [4]

非在研机构-

权益机构

Ipsen SA

Teijin Ltd.

最高研发阶段批准上市

首次获批日期

中国 (2002-03-14),

肢端肥大症恶性类癌综合征

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)、孤儿药 (韩国)

登录后查看时间轴

结构/序列

分子式C56H73N11O12S2

InChIKeyDEXPIBGCLCPUHE-UISHROKMSA-N

CAS号127984-74-1

Sequence Code 26246302

来源: *****

关联

105

项与醋酸兰瑞肽相关的临床试验

NCT06807437

/ Not yet recruiting临床3期IIT

A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula

This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.

开始日期2025-06-28

申办/合作机构

SWOG

[+1]

NCT06878664

/ Not yet recruiting临床3期IIT

Randomized Interval Assessment Trial of Lu177-Dotatate Every 8 Versus Every 16 Weeks in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (NETs) to Lower TOxicity

This is a randomized Phase II/late phase I de-escalation clinical trial with approved investigational medicinal products in new use condition, low intervention.
Disease under study Patients with unresectable or metastatic, slowly progressive, well-differentiated (Grade1 and Grade2), somatostatin receptor-positive midgut neuroendocrine tumors (GEP-NETs).
It is planned to randomize 166 patients with a histologically confirmed diagnosis of slowly progressive grade 1 or grade 2 advanced midgut neuroendocrine tumors (NETs) candidates to receive 177Lu-Dotatate targeted radioligand therapy (RLT). Patients are required to have SSTR+ disease, as evidenced on somatostatin receptor imaging. Patients will be randomized into two arms:
1. control arm: regimen 177Lu-Dotatate every 8 weeks (q8w)
2. experimental arm: regimen 177Lu-Dotatate every 16 weeks (q16w)
Research hypothesis: Less intensive somatostatin-receptor (SST) targeted radioligand therapy (RLT) (7.4 GBq/cycle 177Lu-Dotatate every 16 weeks x 4 cycles) is associated with less severe hematological toxicities and may mitigate the risk to develop therapy-related myeloid neoplasms (t-MN) with similar antitumor efficacy in slowly growing gastrointestinal grade 1-2 NETs.

开始日期2025-05-01

申办/合作机构

Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)

[+1]

ACTRN12624000390583

/ Recruiting临床1期IIT

Phase I, open-label, sequential-group, three-cohort study to evaluate the pharmacokinetic profile, the safety and the tolerability of a single injection of lanreotide Extended-Release Formulation (ERF) at doses of 120 mg and 240 mg in healthy volunteers

开始日期2024-03-04

申办/合作机构-

100 项与醋酸兰瑞肽相关的临床结果

登录后查看更多信息

100 项与醋酸兰瑞肽相关的转化医学

登录后查看更多信息

100 项与醋酸兰瑞肽相关的专利（医药）

登录后查看更多信息

1,491

项与醋酸兰瑞肽相关的文献（医药）

2025-06-01·JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Potential P-glycoprotein (P-gp) inhibitors from SuperDRUG2 database toward reversing multidrug resistance in cancer treatment: Database mining, molecular dynamics, and binding energy estimations

Article

作者: Shoeib, Tamer ; Tallima, Hatem ; Abdelrahman, Alaa H M ; Abdeljawaad, Khlood A A ; Mekhemer, Gamal A H ; Sidhom, Peter A ; Hegazy, Mohamed-Elamir F ; El-Tayeb, Mohamed A ; Sayed, Shaban R M ; Ibrahim, Mahmoud A A

P-glycoprotein (P-gp) transporter is included in the failure of various carcinoma chemotherapeutics because of the multidrug resistance (MDR) phenomenon, in which the chemotherapeutic drugs are eliminated from target cells. Consequently, inhibiting P-gp transporter function is a prospective strategy for cancer treatment. In the current study, the SuperDRUG2 database containing >4600 pharmaceutical compounds was virtually screened toward the P-gp transporter utilizing the docking predictions. For inhibitors with a docking score lower than -10.5 kcal/mol, molecular dynamics (MD) simulations were performed, accompanied by binding energy evaluations using the MM-GBSA approach. In accordance with the MM-GBSA//100 ns MD, angiotensin amide (SD003508), terlipressin (SD002603), argipressin (SD002535), and lanreotide (SD001365) exhibited potential binding affinities against the P-gp transporter with ΔG_binding < -120.0 kcal/mol. The outstanding consistency of the investigated inhibitors inside the P-gp binding pocket was shown by the post-dynamics analyses. Additionally, MD simulations of the inhibitor-P-gp complexes in a POPC membrane environment were conducted to mimic the physiological conditions. These results demonstrated that angiotensin amide, terlipressin, argipressin, and lanreotide are promising P-gp inhibitors and deserve additional in-vitro/in-vivo studies.

2025-06-01·Pituitary

Pasireotide as first line medical therapy for selected patients with acromegaly

Article

作者: Olarescu, Nicoleta C ; Bollerslev, Jens ; Wiedmann, Markus K H ; Heck, Ansgar ; Dahlberg, Daniel ; Atai, Shahriar ; Jørgensen, Anders P

Abstract:

Background and purpose:

In acromegaly, growth hormone (GH) excess and pituitary tumours are typically managed through transsphenoidal surgery, often in combination with somatostatin receptor ligands (SRLs) given either before or following surgery. Although first-generation SRLs (lanreotide and octreotide) are efficacious in many patients, some exhibit resistance.

Methods:

We present the efficacy of the second-generation SRL, pasireotide, in six patients anticipated to be resistant to first-generation SRLs. The patients had large, hyperintense tumors on T2-weighted MRI and sparse granulation pattern by histology.

Results:

Over three to eight months, pasireotide reduced tumour volume in all patients and improved GH and IGF-1 levels. Visual field defects normalised. Despite hyperglycemia, requiring antidiabetic treatment in two patients, pasireotide proved effective as a first pharmacological therapy.

Conclusion:

This series supports the use of pasireotide for rapid tumour control and GH reduction, in selected patients with complex and large tumours, likely to be resistant to first-generation SRLs. This approach expands the therapeutic options for managing the most challenging cases enhancing the potential for other subsequent treatment modalities.

2025-04-01·REVIEWS IN ENDOCRINE & METABOLIC DISORDERS

Nutritional status and gastroenteropancreatic neuroendocrine neoplasms: lights and shadows with a clinical guide from the NIKE Group

Review

作者: Filice, Alessia ; Messina, Erika ; Puliani, Giulia ; Colao, Annamaria ; Mazzilli, Rossella ; Albertelli, Manuela ; Prinzi, Antonio ; Alessi, Ylenia ; Minotta, Roberto ; Isidori, Andrea ; Barrea, Luigi ; Cozzolino, Alessia ; Sesti, Franz ; D’Aniello, Francesco ; Jaafar, Simona ; Pandozzi, Carla ; Mikovic, Nevena ; Verde, Ludovica ; Centello, Roberta ; La Salvia, Anna ; Gay, Stefano ; Zamponi, Virginia ; Malandrino, Pasqualino ; Liccardi, Alessia ; Cannavale, Giuseppe ; Fanciulli, Giuseppe ; Arecco, Arianna ; Grillo, Federica ; Gaudenzi, Germano ; Guarnotta, Valentina ; Campolo, Federica ; Verrico, Monica ; Modica, Roberta ; Lavezzi, Elisabetta ; Russo, Flaminia ; Di Molfetta, Sergio ; Ruggeri, Rosaria Maddalena ; Di Sarno, Antonella ; Grossrubatscher, Erika Maria ; Oldani, Monica ; De Cicco, Federica ; Giannetta, Elisa ; Aini, Irene ; Tarsitano, Maria Grazia ; Mancini, Camilla ; Lai, Roberta ; Faggiano, Antongiulio ; Hasballa, Iderina ; Rubino, Manila ; Feola, Tiziana ; Altieri, Barbara ; Benevento, Elio ; Vitale, Giovanni ; Laffi, Alice ; Ferraù, Francesco ; Lania, Andrea

Neuroendocrine neoplasms (NENs) originating in the gastroenteropancreatic (GEP) tract are rare tumors often associated with significant metabolic disturbances and nutritional challenges. This review explores the intricate relationship between nutritional status and the development, progression, and prognosis of GEP-NENs. Through an extensive literature search encompassing studies up to April 2024, we examined various factors, including obesity, malnutrition, metabolic syndrome and type 2 diabetes mellitus, and their roles in the development and progression of GEP-NENs. The review highlights the dual role of obesity, both as a risk factor and a potential prognostic indicator, drawing attention to the 'obesity paradox' observed in cancer research. Additionally, we discuss the impact of malnutrition on patient outcomes and emphasize the need for comprehensive nutritional assessments beyond BMI. This analysis highlights the importance of incorporating nutritional interventions into preventive and therapeutic strategies for GEP-NEN patients. Future research should further clarify these associations and develop personalized nutritional management protocols to improve patient prognosis and quality of life. Acronyms adopted in the text and tables: AOR: adjusted odd ratio, BIA: Bioelectrical Impedance Analysis, BMI: Body Mass Index, CI: confidence interval, CLARINET: Controlled Study of Lanreotide Antiproliferative Response in Neuroendocrine Tumor, FLI: fatty liver index, GEP: gastroenteropancreatic, GLIM: global leadership into malnutrition, HR: hazard ratio, MS: metabolic syndrome, MUST: malabsorption universal screening tool, NEC: neuroendocrine carcinoma, NENs: Neuroendocrine neoplasms, NETs: Neuroendocrine tumors, NRS: Nutritional Risk Screening, OR: odd ratio, OS: overall survival, PFS: progression-free survival, RR: risk ratio, SGA: Subjective Global Assessment, T2DM: type 2 diabetes mellitus, VAI: visceral adiposity index, WD: well-differentiated.

111

项与醋酸兰瑞肽相关的新闻（医药）

2025-04-28

·健识局

肢端肥大症新药在华获批上市

近日，国家药品监督管理局发布的药品批准证明文件送达信息显示，Recordati集团中国全资子公司锐康迪（北京）医药有限公司的注射用双羟萘酸帕瑞肽微球（商品名：赛尼芬）获批上市，适用于治疗无法手术或手术未治愈，且通过另一种生长抑素类似物治疗控制不佳的成人肢端肥大症患者。肢端肥大症是一种因生长激素和胰岛素样生长因子-1过量分泌引发的罕见疾病。该病已经列入中国罕见病目录，通常由脑垂体的良性肿瘤引起。长期暴露在这些激素下，患者会出现手、脚及面部特征的明显增大，更严重的是，这种疾病严重影响健康，显著提高患者死亡风险，导致心脏病、高血压及其他并发症。此前，双羟萘酸帕瑞肽已在欧洲和美国获得监管机构的批准用于肢端肥大症治疗。在一项名为PAOLA的3期研究中，该药显示出优于现有治疗方法的效果，即使在患者此前已经接受过octreotide或lanreotide的治疗情况下，依然取得了更好的生化控制。研究期间，患者对长效帕瑞肽的耐受性良好，药物不仅显著降低了GH和IGF-I水平，还能在长时间内维持这种控制，改善患者的症状。运营｜廿十三南方医大又有领导落马；外籍医生可以开诊所；AI医疗出新政策OK镜，卖不动了君实生物，2025没有退路

上市批准临床3期

2025-04-25

·PRNewswire

CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU

LUND, Sweden, April 25, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for market authorization of Oczyesa®, octreotide subcutaneous depot (CAM2029), for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.1 "We are pleased with the CHMP's positive recommendation for market authorization for Oczyesa octreotide monthly depot for the treatment of acromegaly", says Fredrik Tiberg, President & CEO at Camurus. "Oczyesa has the potential to advance the standard of care for patients living with acromegaly by enhancing octreotide plasma exposure and enabling easy and convenient once-monthly self-administration by patients using an autoinjector pen." The CHMP positive opinion is backed by a comprehensive clinical program comprising seven clinical studies, including two Phase 3 studies. The ACROINNOVA 1 study demonstrated that treatment with Oczyesa results in a significantly higher proportion of patients achieving normalized insulin growth-factor-1 (IGF-1) levels compared to placebo. The persistence of mean IGF-1 values and reduction of symptoms were confirmed over 52 weeks in the ACROINNOVA 2 study. Furthermore, the study showed improvements in symptoms, quality of life, and treatment satisfaction scores after 52 weeks of treatment with Oczyesa compared to standard of care (SoC) at study baseline.2,3 The most common side effects included gastrointestinal disorders, nervous system disorders, hepatobiliary disorders, metabolism and nutritional disorders, and injection site reactions.1 A final decision on the marketing authorization of Oczyesa based on the CHMP recommendation is anticipated from the European Commission in mid-2025. For more information Fredrik Tiberg, President & CEO Tel. +46 (0)46 286 46 92 [email protected] Fredrik Joabsson, Chief Business Development Officer Tel. +46 (0)70 776 17 37 [email protected] About acromegaly Acromegaly is a rare, progressive disease, typically caused by a tumor of the pituitary gland producing excess growth hormone and stimulating increased insulin growth factor-1 (IGF-1) levels. This results in abnormal growth of bone and tissue, enlarged hands, feet, facial features and inner organs, and symptoms such as fatigue, joint pain, headache, visual field defects, excessive sweating, and paresthesia.4 Inadequate biochemical and symptom control can have detrimental impacts on quality of life and mortality of patients with acromegaly.5,6 The prevalence of acromegaly is estimated to about 60 cases per million.7 About Oczyesa® (CAM2029) CAM2029 is a ready-to-use, long-acting subcutaneous depot of octreotide under development for the treatment of three chronic and severe disease indications: acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET), and polycystic liver disease (PLD). The CAM2029 clinical program for acromegaly comprises of seven clinical trials, including four Phase 1 studies, one Phase 2 study, and two Phase 3 studies within the ACROINNOVA clinical program. CAM2029 has demonstrated an approximate five-fold higher bioavailability compared to the currently approved, long-acting, intramuscular (IM) octreotide.8 In the Phase 3 ACROINNOVA program, CAM2029 showed superior biochemical control compared to placebo as well as improvements in symptom control, treatment satisfaction, and quality of life compared to standard-of-care (SoC) at baseline with first-generation somatostatin receptor ligands (SRLs), octreotide and lanreotide. The safety profile of CAM2029 was consistent with SoC with no new findings.2,3 CAM2029 is formulated using Camurus' proprietary FluidCrystal® technology. The product is designed for convenient once-monthly, subcutaneous self-administration using a pen with a hidden, small-gauge needle. The product is stored at room temperature and should not be refrigerated. CAM2029 has received orphan drug designation for acromegaly (EU) and for polycystic liver disease (EU and US). About Camurus Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit and LinkedIn. References Oczyesa® Summary of Opinion. Ferone, D., et al. J Clin Endocrinol Metab. Published 8 October, 2024. Press release 15 July, 2024: Colao A., et al. Acromegaly. Nat Rev Dis Primers. 2019;5(1):20. Webb SM, et al. Quality of Life in Acromegaly. Neuroendocrinology. 2016;103(1):106-111. Fleseriu M, et al Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022 Nov;10(11):804-826. Crisafulli S., et al. Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinology. 2021; 185:251-63. Summary of Product Characteristics, Sandostatin LAR 20 mg: This information was submitted for publication at 4:00 pm CET on 25 April 2025. This information was brought to you by Cision The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果临床3期孤儿药寡核苷酸上市批准

2025-04-25

·医药观澜

治疗成人肢端肥大症，长效疗法在中国获批上市！

今日（4月25日），中国国家药监局（NMPA）官网最新公示，Recordati集团中国全资子公司锐康迪医药申报的注射用双羟萘酸帕瑞肽微球的上市申请已获得批准。根据NMPA药品审评中心（CDE）优先审评公示，该药本次获批用于治疗无法手术或手术后未治愈和通过另一种生长抑素类似物治疗控制不佳的成人肢端肥大症患者。公开资料显示，这是一款长效帕瑞肽产品（pasireotide pamoate）。此前，博鳌乐城维健罕见病临床医学中心已经引进该产品治疗肢端肥大症患者。截图来源：NMPA官网肢端肥大症是由生长激素（GH）和胰岛素样生长因子-1（IGF-1）分泌过多引起的一种罕见的、使人衰弱的内分泌疾病，该病已经在中国被纳入《第二批罕见病目录》。在大多数情况下，这种疾病是由脑垂体上的非癌性肿瘤引起的。长期暴露于生长激素和IGF-1可能会导致患者经历极端的身体变化，包括手、脚和面部特征的增大。肢端肥大症使患者死亡率增加2~3倍，并和严重的健康并发症有关，包括心脏病、高血压、糖尿病、关节炎和结肠癌。肢端肥大症治疗的总体目标是抑制GH过度分泌，降低IGF-1的水平，减少并发症，降低死亡率。长效帕瑞肽（即双羟萘酸帕瑞肽）为第二代生长抑素类似物（SRL），生长抑素正是GH分泌的生理抑制剂。与第一代SRL相比，长效帕瑞肽增强了生长抑素受体（SSTR）的结合谱，即对SSTR1、2、3和SSTR5亚型具有高亲和力，尤其对SSTR5的亲和力最高，具有更好的临床和生化控制率，且安全性良好。对于不能选择手术或手术后尚未治愈，且使用第一代SRL治疗不能充分控制的成人肢端肥大症患者，长效帕瑞肽可以作为新的治疗选择。此前，双羟萘酸帕瑞肽已获得欧洲药品管理局（EMA）和美国FDA批准治疗成人肢端肥大症患者。根据文献报道，在一项3期PAOLA研究中，尽管入组患者在研究开始前接受了≥6个月的octreotide/lanreotide（活性对照）治疗，但肢端肥大症仍未得到控制。与继续使用活性对照药物治疗相比，更多的患者在使用长效帕瑞肽治疗6个月后达到了生化控制。在该核心研究结束时，接受40或60mg长效帕瑞肽治疗后生化指标受控的患者可以在延长期研究中继续使用相同剂量；如果未受控，则可接受60mg的长效帕瑞肽治疗。对于使用活性对照药物但未受控的患者，则切换为40mg的帕瑞肽治疗，如果在延长期研究的第16周仍未受控，则增加剂量。在延长期研究期间，共有173名患者接受了长效帕瑞肽治疗。结果显示，长效帕瑞肽的耐受性良好且疗效显著，能够长期维持肢端肥大症患者的生化控制并改善关键症状。长效帕瑞肽在长达5.8年的治疗期间有效且持续地降低了GH和IGF-I水平；37.0%的患者在核心或延长期研究内的某个时间点达到了GH <1.0 µg/L和正常IGF-I水平。参考资料：[1]2025年04月25日药品批准证明文件送达信息 . From https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20250425151104133.html[2]肢端肥大症患者治疗新选择！创新药长效帕瑞肽可在乐城申请使用 . Retrieved Oct 9， 2023. From https://mp.weixin.qq.com/s/6hJIqHK_P37So8FIRaJFNw[3]Recordati Rare Diseases, Inc. Announces Transfer of U.S. Marketing Rights to SIGNIFOR® (pasireotide) Injection and SIGNIFOR LAR® (pasireotide) for Injectable Suspension. Retrieved Feb 20， 2020. From https://www.recordatirarediseases.com/us/node/169[4] Colao A, Bronstein MD, Brue T, De Marinis L, Fleseriu M, Guitelman M, Raverot G, Shimon I, Fleck J, Gupta P, Pedroncelli AM, Gadelha MR. Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. Eur J Endocrinol. 2020 Jun;182(6):583. doi: 10.1530/EJE-19-0762. 版权声明：本文欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权及其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

优先审批临床3期上市批准

100 项与醋酸兰瑞肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04666	醋酸兰瑞肽	H01CB03	DB06791

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
垂体肿瘤	日本	Teijin Ltd.	2021-01-15
巨人症	日本	Teijin Ltd.	2013-01-08
胃肠胰神经内分泌肿瘤	澳大利亚	Ipsen Pty Ltd.	2003-09-11
类癌	韩国	Ipsen Ltd.	2002-08-08
神经内分泌肿瘤	韩国	Ipsen Ltd.	2002-08-08
肢端肥大症	中国	Ipsen Pharma Biotech SAS	2002-03-14
恶性类癌综合征	中国	Ipsen Pharma Biotech SAS	2002-03-14

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肺神经内分泌肿瘤	临床3期	美国	Ipsen SA	2017-03-06
肺神经内分泌肿瘤	临床3期	奥地利	Ipsen SA	2017-03-06
肺神经内分泌肿瘤	临床3期	加拿大	Ipsen SA	2017-03-06
肺神经内分泌肿瘤	临床3期	丹麦	Ipsen SA	2017-03-06
肺神经内分泌肿瘤	临床3期	法国	Ipsen SA	2017-03-06
肺神经内分泌肿瘤	临床3期	德国	Ipsen SA	2017-03-06
肺神经内分泌肿瘤	临床3期	意大利	Ipsen SA	2017-03-06
肺神经内分泌肿瘤	临床3期	荷兰	Ipsen SA	2017-03-06
肺神经内分泌肿瘤	临床3期	波兰	Ipsen SA	2017-03-06
肺神经内分泌肿瘤	临床3期	西班牙	Ipsen SA	2017-03-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03289741 (CTgov)	临床4期	神经内分泌肿瘤	51	Octreotide+LAR Lanreotide (Octreotide Then Lanreotide)	簾糧網願糧醖積淵選醖(窪鏇齋鹹選襯築衊遞觸) = 窪壓餘選簾簾夢製襯簾遞憲製淵選願壓衊獵繭 (遞網遞觸積鹽鹹鏇鬱獵, 憲壓襯糧夢糧襯窪壓壓 ~ 醖製壓網網鏇艱夢齋醖) 更多	-	2025-05-09
NCT03289741 (CTgov)	临床4期	神经内分泌肿瘤	51	Octreotide+LAR Lanreotide (Lanreotide Then Octreotide)	製鏇蓋壓廠鑰範鑰蓋鏇(構齋憲窪餘觸夢網齋壓) = 鏇簾鹹獵蓋願壓遞顧鹽範築膚積願鏇齋壓鹹鹽 (醖淵鹹艱築糧觸齋淵構, 蓋蓋鏇範壓鬱願鏇壓鹹 ~ 艱襯構襯鏇艱醖艱餘願) 更多	-	2025-05-09
ASCO_GI2025	N/A	胃神经内分泌肿瘤辅助 ki67	35	Somatostatin analogs (long-acting releasing octreotide 30 mg)	觸壓蓋簾蓋壓觸構製廠(蓋廠鬱廠製觸鬱壓鹽壓) = 膚廠鑰衊窪鏇製衊選鹹築衊遞範遞鑰築築鬱願 (膚鏇醖鬱憲廠鹹觸製醖, 67 ~ NR)	积极	2025-01-23
ASCO_GI2025	N/A	胃神经内分泌肿瘤辅助 ki67	35	Lanreotide 120 mg	觸壓蓋簾蓋壓觸構製廠(蓋廠鬱廠製觸鬱壓鹽壓) = 鏇蓋廠簾糧膚構憲選顧築衊遞範遞鑰築築鬱願 (膚鏇醖鬱憲廠鹹觸製醖, 67 ~ NR)	积极	2025-01-23
NCT04852679 (PALACE, CTgov)	临床3期	胃肠胰神经内分泌肿瘤	43	Lanreotide autogel	艱觸齋廠壓窪鏇餘遞鑰 = 簾鏇夢獵鹹夢膚襯艱鏇積範繭鑰網範鹽醖鑰範 (鏇夢獵製糧範艱廠鏇鑰, 艱鹽簾廠衊顧顧鬱構淵 ~ 願齋醖繭顧膚糧窪夢鬱) 更多	-	2024-10-01
PRESTO 3 (ENDO2023)	N/A	-	94	Lanreotide (Somatuline Autogel syringe)	膚餘鏇憲餘繭築蓋積憲(遞窪構鬱築範餘遞鹽壓) = 範鏇顧構製網窪夢淵願遞鑰構遞積鬱醖選齋醖 (獵蓋築範遞鏇憲網廠窪, 77.5 ~ 92.4)	积极	2023-10-05
NCT02859064 (CTgov)	临床2期	类癌 \| 胃肠胰神经内分泌肿瘤	6	Y-90 microspheres+Lanreotide	網窪獵獵鏇淵繭壓餘壓 = 襯廠簾夢鏇鏇廠積製獵遞繭願襯鏇醖鑰製顧膚 (齋築醖鑰蓋蓋窪鏇網顧, 襯淵壓衊衊範壓壓糧廠 ~ 夢積觸糧範簾夢願鑰壓) 更多	-	2023-07-27
NCT01538966 (CTgov)	N/A	肢端肥大症	76	Pegvisomant+Octreotide LAR+Lanreotide (High Dose SRL + Weekly Pegvisomant)	觸淵觸夢遞鏇憲糧構鬱(夢構製鹽觸憲鏇鹹製顧) = 遞範餘繭齋艱憲繭願選廠齋窪艱襯憲鹹膚選鹽 (選糧簾製蓋淵獵遞膚觸, 1,645.49) 更多	-	2023-01-04
NCT01538966 (CTgov)	N/A	肢端肥大症	76	Pegvisomant+Octreotide LAR+Lanreotide (Low Dose SRL + Daily Pegvisomant)	觸淵觸夢遞鏇憲糧構鬱(夢構製鹽觸憲鏇鹹製顧) = 鹹廠蓋壓構衊窪廠壓淵廠齋窪艱襯憲鹹膚選鹽 (選糧簾製蓋淵獵遞膚觸, 11,158.49) 更多	-	2023-01-04
NCT03043664 (PLANET, CTgov)	临床1/2期	胃肠胰神经内分泌肿瘤	22	Somatuline Depot (lanreotide)+Keytruda (pembrolizumab)	獵憲廠窪遞構範範願淵 = 齋夢憲觸簾憲艱膚簾願糧繭遞艱鑰襯獵築夢餘 (構憲鹹獵繭窪襯繭艱醖, 遞簾餘鬱蓋簾積壓網衊 ~ 築繭願壓鬱襯選艱範餘) 更多	-	2022-09-28
NCT02275338 (Pubmed \| Clin Ther)	临床2期	恶性肠梗阻	52	Lanreotide Autogel 120 mg	簾齋製顧鹽願衊築餘壓(壓廠鑰窪膚廠蓋積襯壓) = 範憲淵積網壓構壓顧憲積艱遞繭繭衊齋構網鹹 (願鑰網築構廠選範蓋壓 )	-	2021-12-01
NCT02288377 (REMINET \| Prodige 31 REMINET, CTgov)	临床2/3期	神经内分泌肿瘤	53	Placebo (Placebo)	繭觸鏇糧廠構選簾鏇廠 = 襯願襯遞廠簾範觸觸壓顧醖築襯繭鑰齋遞壓壓 (衊鬱遞鹹築醖壓窪衊鬱, 膚膚願鹹淵積餘壓壓鏇 ~ 選壓膚獵選網製觸鑰淵) 更多	-	2021-10-04
NCT02288377 (REMINET \| Prodige 31 REMINET, CTgov)	临床2/3期	神经内分泌肿瘤	53	lanreotide (Lanreotide)	繭觸鏇糧廠構選簾鏇廠 = 蓋獵遞構衊廠築獵壓鏇顧醖築襯繭鑰齋遞壓壓 (衊鬱遞鹹築醖壓窪衊鬱, 憲餘廠遞觸夢膚糧願網 ~ 築廠構鑰糧餘壓衊淵餘) 更多	-	2021-10-04